INTRODUCTION
============

Venous thromboembolism (VTE) refers to thrombosis within the vein, commonly in the legs or pelvis (deep vein thrombosis, DVT) and its complication, pulmonary embolism (PE), the condition of thrombi departing from their original generation site into a pulmonary artery ([@b45-bt-25-461]). It is the third leading cause of cardiovascular-related deaths, following acute coronary syndrome and stroke ([@b73-bt-25-461]), with an annual incidence of 1 to 3 times per 1,000 people ([@b34-bt-25-461]; [@b75-bt-25-461]). Moreover, it often leads to long-term complications such as post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension, which impose a significant burden on both patients and the healthcare systems ([@b80-bt-25-461]; [@b9-bt-25-461]).

Pathologic thrombosis or bleeding may occur whenever the hemostatic balance is disturbed due to various health conditions including surgery, trauma, malignancy, and congenital disorders ([@b74-bt-25-461]) and even following chronic cigarrete smoking ([@b70-bt-25-461]). In normal circumstances, hemostasis is maintained through the complex interactions between the vascular system ([@b51-bt-25-461]), coagulation system, fibrinolytic system ([@b54-bt-25-461]) and platelets ([@b47-bt-25-461]). Natural anticoagulants such as tissue factor pathway inhibitors (TFPI), protein C, protein S, and anti-thrombin (AT) also regulate the coagulation process. The fibrinolytic system plays a role by dissolving the fibrin clot during the healing process of an injured blood vessel ([@b99-bt-25-461]; [@b13-bt-25-461]).

Anticoagulants can inhibit thrombosis by altering various pathways within the coagulation system or through targeting thrombin directly by attenuating its generation ([@b65-bt-25-461]). For many years, unfractionated heparins (UFHs) and vitamin K antagonists (VKAs) have been the main options for the prevention and treatment of VTE ([@b27-bt-25-461]). The treatment changed little until low molecular weight heparins (LMWHs), fragments of UFHs, were introduced in the 1980s, simplifying the management of thromboembolism by saving the trouble of frequent coagulation monitoring ([@b99-bt-25-461]). In the 2000s, ultra-low molecular heparins (ULMWHs) were developed in an effort to improve the pharmacokinetic profile of conventional heparin formulations and to lower the risk of heparin-induced thrombocytopenia (HIT) ([@b63-bt-25-461]). However, all forms of heparin require parenteral administration, which is cumbersome for long-term use ([@b25-bt-25-461]). Similarly, oral VKAs have several drawbacks including a wide range of food and drug interactions, as well as the need for frequent monitoring and dose adjustment ([@b38-bt-25-461]).

Over the past decades new oral anticoagulants (NOACs), which more directly and selectively target specific proteins in the coagulation cascade, have been developed, as shown in [Fig. 1](#f1-bt-25-461){ref-type="fig"}. They are conveniently administered in oral, fixed doses without routine monitoring and have fewer interactions than VKAs with foods or drugs ([@b66-bt-25-461]). But NOACs have their own limitations such as lack of reliable coagulation monitoring methods and selective antidotes (except dabigatran), as shown in [Table 1](#t1-bt-25-461){ref-type="table"}. This review summarizes the pharmacologic characteristics of traditional and new anticoagulants, as well as anticoagulants under development, focusing on their advantages and disadvantages.

TRADITIONAL ANTICOAGULANTS
==========================

Vitamin K antagonists
---------------------

VKAs such as coumarin derivatives (e.g., warfarin, acenocoumarol, and phenprocoumon) exert their anticoagulant effects by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (KO), therefore depleting the vitamin K hydroquinone (KH~2~; [@b101-bt-25-461]). The coagulation factors II (thrombin), VII, IX, and X, as well as proteins C and S, require carboxylation, by converting glutamic acid to gamma-carboxyglutamic acid, for their normal functions. The carboxylation procedure requires KH~2~ ([@b2-bt-25-461]). VKAs inhibit vitamin K epoxide reductase complex 1 (VKORC1), an enzyme that catalyzes the reduction of KO to vitamin K, which is then converted to KH~2~ and then oxidized back to KO, concomitantly with gamma-glutamyl carboxylation. The full anticoagulation effect of warfarin is not achieved until the clearance of factor X and prothrombin that have half-lives of 36 and 50 h, respectively ([@b58-bt-25-461]). Because proteins C and S, with relatively short half-lives, initially exert their procoagulant effects, the combined use of VKAs with parenteral agents is required.

The anticoagulant response to warfarin is largely affected by diet, concurrent drugs, and genetic polymorphisms ([@b37-bt-25-461]). The anticoagulant effect of warfarin can be counteracted by vitamin K intake either through food or supplements. A large amount of vitamin K causes warfarin resistance for up to a week because vitamin K accumulated in the liver can bypass VKORC ([@b59-bt-25-461]). The cytochrome P450 enzyme (CYP2C9) is responsible for oxidative metabolism of the warfarin S-isomer, which is five times more potent than the R-isomer. Therefore, the dose-response of warfarin can be influenced by CYP2C9 inhibiting drugs that affect the metabolic clearance of warfarin, especially the S-isomers, such as phenylbutazone, sulfinpyrazone, metronidazole, trimethoprim-sulfamethoxazole, or amiodarone. It is also influenced by genetic polymorphisms in CYP2C9 and VKORC unit 1 genes ([@b28-bt-25-461]). The individuals who carry CYP2C9\*2 or CYP2C9\*3 tend to have higher levels of S-warfarin due to the impaired ability to metabolize it. Since CYP2C9 is also responsible for the metabolism of acenocoumarol, and less importantly for phenprocoumon, polymorphisms of CYP2C9 also affect the efficacy of acenocoumarol and phenprocoumon, although with a lesser extent than with warfarin ([@b95-bt-25-461]). Genetic mutations or an altered expression of the VKORC1 gene can also lead to variable responses, either hyper-sensitivity or resistance to warfarin therapy. Acenocoumarol and phenprocoumon are also influenced by the VKORC1 genotype, especially in the first few months.

Hemorrhage is the most significant and frequent complication related to warfarin, with an annual incidence of major bleeding at a rate of 13 per 100 patients ([@b57-bt-25-461]). The risk of bleeding associated with warfarin is related not only to the degree of anticoagulation but also to patient-related factors and the concurrent use of antiplatelet agents or other drugs ([@b26-bt-25-461]). Bleeding complications can be managed by administering vitamin K, fresh frozen plasma (FFP), prothrombin complex concentrates (PCCs), or recombinant factor VIIa ([@b91-bt-25-461]), which can antagonize the effects of warfarin therapy.

Heparins
--------

Heparins indirectly inhibit thrombin by enhancing the activity of antithrombin (AT), a proteinase inhibitor of coagulation enzymes such as thrombin and factors Xa of the common pathway, as well as IXa, XIa and XIIa of the intrinsic coagulation pathway ([@b40-bt-25-461]). Following a conformational change induced by heparin, AT irreversibly inhibits thrombin via binding its active site. For inactivation of thrombin, heparin must bind simultaneously to thrombin at exosite 2 and AT, forming a ternary complex which requires at least 18 saccharide units ([@b56-bt-25-461]). In contrast, heparin only binds to AT via high-affinity pentasaccharides, for the inhibition of factor Xa, without requiring a bridge between factor Xa and AT. Since most heparin molecules are at least 18 units long, inhibitory activities of heparin against the thrombin and factor Xa are equivalent ([@b35-bt-25-461]). However, the AT-bound heparin weakly inhibits the thrombin, once formed as a ternary heparin-fibrin-thrombin complex, because it can no longer gain access to the exosite 2 already occupied. Furthermore, AT-bound heparin is unable to inhibit factor Xa bound to activated platelets ([@b89-bt-25-461]).

**Unfractionated heparins (UFH):** Unfractionated heparin (UFH) is heterogeneous in terms of molecular size, anticoagulant activity and pharmacokinetics ([@b30-bt-25-461]). The molecular weight of UFH ranges from 3,000 to 30,000 Da, with an average of 15,000 Da (approximately 45 saccharide units). Only 20--50% of UFH chains contain the high-affinity pentasaccharide unit necessary for activating AT ([@b62-bt-25-461]). Heparin molecules without a pentasaccharide unit have minimal activity at therapeutic concentrations. Low-affinity heparin can inhibit thrombin via heparin cofactor ([@b90-bt-25-461]) as well as factor Xa generation, through AT-independent mechanisms ([@b30-bt-25-461]).

Besides the multiple anticoagulant mechanisms, heparin involves multiple clearance mechanisms including both rapid, saturable and slow, non-saturable processes ([@b39-bt-25-461]). The rapid phase of heparin clearance occurs through binding to macrophages and endothelial cells at saturable sites on the cell membrane and subsequent depolymerization, whereas the slow clearance mechanism is through the kidneys. Because low doses of heparins initially undergo the saturable and dose-dependent clearance, the effect of heparin is not linear, although both intensity and duration of heparin activity may increase with escalating doses. As a result, the pharmacokinetics and pharmacodynamics of UFH are unpredictable.

Additionally, UFH has a number of limitations such as a short duration of action with a half-life of 60 min, poor bioavailability after subcutaneous injection, and an immune-mediated reaction, a life-threatening adverse event ([@b50-bt-25-461]). Heparin complexes with an endogenous platelet factor 4 (PF4), which undergoes conformational changes and becomes immunogenic, leading to the generation of heparin-PF4 antibodies ([@b49-bt-25-461]). The heparin-PF4-IgG immune complex then activates platelets and causes the release of microparticles, platelet consumption and peripheral thrombocytopenia, and also endothelial injury and activation ([@b77-bt-25-461]). Heparin's affinity for PF4 depends on molecular weights and chain lengths ([@b4-bt-25-461]), thus accounting for the increased incidence of thrombocytopenia by UFH when compared with LMWH.

The effect of UFH can be reversed by intravenously administering protamine sulfate that binds to heparin and forms a stable salt ([@b31-bt-25-461]). This can be advantageous in situations of cardiac surgery or treating critically ill patients who may require rapid reversal of the anticoagulation effect.

**Low molecular weight heparins (LMWH):** LMWH is a mixture of polymers with molecular weights that vary from 1,000 to 10,000 Da, with a mean molecular weight between 4,000 and 5,000 Da, approximately one third the size of UFH ([@b36-bt-25-461]). Since LMWHs are prepared by various chemical or physical depolymerizations of heparin, each LMWH has unique characteristics in terms of molecular weight, polysaccharide chain length distributions, and pharmacological properties that may influence pharmacokinetic properties and anticoagulant activity profiles ([@b67-bt-25-461]). Since 50 to 75% of LMWH species have a length of less than 18 saccharides, which will inhibit only factor Xa, the selectivity ratio of activity against factor Xa to thrombin varies between 4:1 and 2:1, depending on their preparations ([@b41-bt-25-461]). Because LMWH mostly undergoes renal elimination, its biologic half-life may be prolonged in cases of renal insufficiency, especially for those with lower molecular weights such as enoxaparin or nadroparin ([@b82-bt-25-461]).

In addition to the convenience of subcutaneous administration and almost 100% subcutaneous bioavailability, LMWH has several advantages over UFH in terms of pharmacological characteristics ([@b40-bt-25-461]). The low protein binding of LMWH makes anticoagulant effects more predictable, which allows for a fixed or body weight-based dose regimen without the need for frequent monitoring ([@b40-bt-25-461]). Low nonspecific binding to macrophages and endothelial cells increases the plasma half-life of LMWH. In addition, the lower binding to platelets, PF4 and osteoclasts may reduce the risk of HIT and osteoporosis.

Unlike UFH's complete neutralization activity of anti-factor Xa, protamine sulfate reverses only about 60% of the anti-factor Xa activity of LMWH ([@b102-bt-25-461]). This may be due to the fact that protamine favors the regions of larger heparin chains, and an effective antidote for the residual smaller chains in LMWHs is not available ([@b83-bt-25-461]). Furthermore, the subcutaneous administration of heparins is more difficult to completely reverse.

**Ultra-low molecular weight heparins (ULMWHs):** Ultra-low molecular weight heparins (ULMWHs), also known as an indirect factor Xa inhibitors, are synthetic analogues of the pentasaccharide contained within heparins, with an average molecular weight of less than 3,000 Da ([@b98-bt-25-461]). These small, homogeneous drugs have been developed on the basis that higher selectivity in the activity against factor Xa or thrombin would produce similar or better efficacy than LMWHs, but have a lower risk of bleeding and HIT. ULM-WHs also exhibit anticoagulant efficacy through the selective inhibition of factor Xa via the unique pentasaccharide unit ([@b36-bt-25-461]).

ULMWHs only exhibit the anti-factor Xa effect when binding to AT and are devoid of other functional components of heparins such as the release of TFPI from the vascular endothelium, the formation of complexes with PF4, and profibrinolytic actions. It is likely that the heparin chains must be of a sufficient length to form a complex with PF4 for binding to antibodies, which is a pathological mechanism of HIT ([@b76-bt-25-461]). Besides anticoagulant activity which is weaker than that of UFH or LMWHs, ULMWHs show anti-angiogenic, anti-metastatic and anti-inflammatory activities ([@b29-bt-25-461]).

The hepatic clearance of heparin is believed to involve the stabilin-2-receptor that requires heparin chains longer than decasaccharides for binding ([@b71-bt-25-461]). Therefore, unlike UFH, ULMWHs never reach the size needed for hepatic clearance and therefore depend heavily on renal clearance ([@b81-bt-25-461]).

ULMWHs offer several advantages over conventional heparins such as a higher bioavailability, rapid onset of action with longer biological half-lives, and a lower risk of bleeding, as well as osteoporosis. Because of the absence of binding to other plasma proteins, ULMWHs have predictable pharmacokinetics with almost 100% bioavailability. However, no antidote is available for bleeding associated with ULMWHs, whereas protamine sulfate can neutralize UFH completely and LMWHs partially. Unlike the impermeability of LMWHs or UFHs through the placental or blood-brain barrier, ULMWHs are able to partially pass the blood-brain barrier ([@b42-bt-25-461]).

NEW ANTICOAGULANTS
==================

The newer anticoagulants offer superior therapeutic control over coagulations with minimal bleeding complications. They directly target either thrombin or factor Xa in the coagulation cascade, which is pharmacologically distinct from traditional anticoagulant agents ([Fig. 2](#f2-bt-25-461){ref-type="fig"}). Since the amount of activated coagulation factors is amplified at each level of the coagulation cascade, direct inhibition of the final products from both the intrinsic and extrinsic coagulation pathways (factor Xa and thrombin) can provide more effective anticoagulation.

Direct thrombin inhibitors
--------------------------

Thrombin is an end product in the coagulation cascade, which converts soluble fibrinogen to insoluble fibrin. It amplifies coagulation by activating factors V and VIII on the surface of platelets and platelet-bound factor XI, stimulating platelets and generating more thrombin. By activating XIII, it also accelerates the formation of cross-linked fibrins and clot stabilization. In addition to its procoagulant role, thrombin plays a role in growth factor synthesis, cell proliferation, prostaglandin I~2~ synthesis, and chemotaxis of polymorphonuclear cells ([@b17-bt-25-461]). Therefore, inhibition of thrombin may provide benefits in addition to anticoagulation ([@b7-bt-25-461]).

The antithrombotic action of heparin occurs through binding to both AT and thrombin's exosite 2, a heparin-binding domain, simultaneously. Heparin also can act as a bridge between fibrin and thrombin, enhancing thrombin's affinity for fibrin and increasing the amount of fibrin-bound thrombin. Because the fibrin-heparin-thrombin complex, therefore, occupies not only exosite 2 but also exosite 1 (fibrin-binding site), fibrin-bound thrombin is protected from inhibition by the heparin-AT complex and remains active, resulting in further thrombus generation ([@b100-bt-25-461]). As such, heparin is relatively ineffective at inhibiting thrombin propagation ([@b21-bt-25-461]).

Unlike heparins, direct thrombin inhibitors (DTIs) act without a preceding interaction with AT and directly suppress thrombin, as well as its interaction with its substrates ([@b21-bt-25-461]). DTIs block the action of thrombin by binding to the catalytic site (univalent) or to both the catalytic site and exosite 1 (bivalent) ([@b5-bt-25-461]). Therefore, DTIs can inhibit both free and fibrin-bound thrombin. In addition, there are other advantages such as more predictable anticoagulant effects due to the absence of interaction with plasma proteins, not being neutralized by PF4, the inhibition of thrombin-induced platelet aggregation and absence of immune-mediated thrombocytopenia ([@b53-bt-25-461]).

Bivalent DTIs include recombinant hirudins (e.g., lepirudin and desirudin) and a synthetic hirudin, bivalirudin ([@b21-bt-25-461]). Bivalent DTIs form an irreversible complex with thrombin, but bivalirudin, which is slowly cleaved by thrombin once bound, restores the catalytic function of thrombin ([@b53-bt-25-461]). As a result, thrombin inhibition using bivalirudin is temporary, which may contribute to its low bleeding risk compared with recombinant hirudins ([@b69-bt-25-461]). Bivalirudin is mainly cleared by proteolysis and hepatic metabolism, whereas recombinant hirudins predominantly undergo renal excretion.

Univalent DTIs, such as argatroban, ximelagatran, and dabigatran exteilate, non-covalently and reversibly bind to thrombin, leaving a small fraction of free thrombin ([@b21-bt-25-461]). Reversible and selective binding to thrombin accompanies a minimal risk of bleeding and rapid restoration of hemostasis to baseline upon discontinuation. Like recombinant hirudins, argatroban is a parenteral DTI but is metabolized by the liver ([@b48-bt-25-461]).

Ximelagatran, a prodrug of melagatran, is the first oral DTI, which represents a new era of anticoagulation for the prevention and treatment of VTE. Although it was withdrawn from the market due to a risk of significant hepatotoxicity, ximelagatran demonstrated improved antithrombotic efficacy when compared with traditional anticoagulation therapies ([@b24-bt-25-461]). A few years later, dabigatran etexilate, the second oral DTI, was developed with some improvements such as no risk of hepatotoxicity and low potential for food or drug interactions. Following oral absorption, dabigatran etexilate is rapidly converted into its active form, dabigatran, by nonspecific serum esterase without the involvement of cytochrome P450 enzymes or other oxidoreductases. Therefore, dabigatran etexilate has a low potential for interacting with drugs ([@b88-bt-25-461]). Approximately 80% of circulating dabigatran is excreted unchanged via the kidneys and the remainder is conjugated with glucuronic acid. The conjugated dabigatran, which exhibits similar properties to the unconjugated form, is predominantly excreted via the bile.

Currently, none of the DTIs, except dabigatran, have direct reversal agents available for use. Recombinant factor VIIa, activated prothrombin complex concentrate (aPCC), activated charcoal, desmopressin and von Wilebrand factor concentrate have been tried in various studies ([@b60-bt-25-461]; [@b6-bt-25-461]). Dabigatran effects can be reversed within minutes of intravenous administration of idarucizumab, a humanized monoclonal antibody, which binds tightly and prevents dabigatran from binding to thrombin ([@b85-bt-25-461]).

Direct factor Xa inhibitors
---------------------------

Factor Xa is a primary site of amplification for coagulation factors, generating about 1,000 thrombin molecules from a single Xa molecule ([@b61-bt-25-461]). Factor Xa binds to negatively charged phospholipid surfaces, which are exposed on activated platelets, together with factor Va to form the prothrombinase complex, the activator that converts prothrombin into thrombin. The conversion of fibrinogen to fibrin, the basic building block of all blood clots, is then catalyzed by thrombin. The rate of prothrombin activation by factor Xa in a prothrombinase complex is dramatically increased, thereby rapidly facilitating thrombin generation and plug formation at sites of injury. Whereas heparin inhibits factor Xa and thrombin to a similar degree, LMWHs have a relatively greater inhibitory effect against factor Xa, which has drawn attention as a potential anticoagulant target ([@b30-bt-25-461]). The interest of factor Xa as a drug target was further solidified by positive results from the use of fondapariunux, a parenteral indirect factor Xa inhibitor ([@b104-bt-25-461]).

Unlike indirect factor Xa inhibitors which are dependent on AT, direct factor Xa inhibitors interact directly and selectively with factor Xa and inhibit both free and bound forms of factor Xa without affecting platelet aggregation ([@b81-bt-25-461]). They are also associated with reduced incidence of rebound thrombosis compared to direct and indirect thrombin inhibitors ([@b72-bt-25-461]). Because direct factor Xa inhibitors have good bioavailability with rapid onset of action, there is no need for bridging therapy with a parenteral agent ([@b12-bt-25-461]). In general, they exhibit linear pharmacokinetics and display predictable anticoagulation effects following oral administration. All three agents, rivaroxaban, apixaban, and edoxaban, are excreted through the kidneys to varying degrees and have elimination half-lives much shorter than the VKAs. Rivaroxaban has a dual mechanism of excretion, with two-thirds of the administered dose excreted through the urine as either unchanged or inactive metabolites and one-third of the dose excreted through feces ([@b72-bt-25-461]). Only 25% of an apixaban dose is eliminated by the kidneys with the remainder excreted via the fecal route ([@b22-bt-25-461]). Edoxaban undergoes multiple elimination pathways with 35% excreted in the urine. Over 70% of the dose is excreted unchanged ([@b8-bt-25-461]).

The substantial benefits of oral factor Xa inhibitors are unfortunately accompanied by a high incidence of major and clinically relevant bleeding including gastrointestinal bleeding ([@b15-bt-25-461]). Moreover, all three factor Xa inhibitors are CYP3A4 and P-glycoprotein (P-gp) substrates that carry potential drug interaction issues. The CYP3A4 and/or P-gp inhibitors, as well as inducers, might impact the concentration of oral factor Xa inhibitors, leading to increased risk of bleeding or thrombosis ([@b84-bt-25-461]).

Potential antidotes for reversing anticoagulation caused by factor Xa inhibitors are currently under development ([@b3-bt-25-461]). Andexan*et al*fa is a recombinant, modified factor Xa protein with a mutation on the catalytic site that abolishes the procoagulant property, which binds to direct and indirect factor Xa inhibitors in the blood ([@b16-bt-25-461]). PER977 (e.g., arapazine and ciraparantag) binds to factor Xa inhibitors, as well as direct and indirect thrombin inhibitors, through noncovalent bonds and electrical charge interactions ([@b18-bt-25-461]).

ANTICOAGULANTS UNDER DEVELOPMENT
================================

Both thrombin and factor Xa inhibitors have been extensively evaluated in several large clinical trials for the prevention and treatment of thromboembolic disorders. Despite their excellent efficacy compared to traditional agents, these drugs have their own drawbacks. Bleeding is still a major issue, with no reliable diagnostic test available to safely monitor the therapeutic dosage, as well as a lack of effective reversal agents ([@b45-bt-25-461]; [@b68-bt-25-461]; [@b44-bt-25-461]).

A variety of anticoagulant strategies, targeting other steps in coagulation, are in development to attempt to overcome the limitations of currently used agents. Drugs that target the tissue factor (TF)-factor VIIa complex inhibit the initiation of coagulation. Propagation of coagulation can be inhibited by drugs that target factors IXa or Xa or by agents that inactivate their respective cofactors, factors VIIIa and Va.

Tissue factor pathway inhibitors
--------------------------------

Following vascular injury, TF, also known as thromboplastin, is exposed to the blood and binds to factor VIIa, which sets off the extrinsic coagulation pathway ([@b103-bt-25-461]). The TF-factor VIIa complex activates factors X and IX. Additionally, activated factor IX forms a complex with factor VIIIa, which also activates factor X. Factor Xa then binds to factor Va to form prothrombinase, an enzymatic complex which rapidly converts prothrombin to thrombin. The TF activity and the extrinsic pathway are regulated by the tissue factor pathway inhibitor (TFPI). It inhibits factor Xa directly and the TF-factor VIIa complex in an Xa-dependent fashion. The factor Xa-dependent inhibition of the TF-factor VIIa complex generates an inactive quaternary complex in the plasma membrane.

Inhibition of TF-factor VIIa complex by recombinant TFPI was examined in various models of disseminated intravascular coagulation such as sepsis. Tifacogin, a recombinant TFPI expressed in *Saccharomyces cerevisae*, inhibits factor VIIa in a factor Xa-dependent fashion ([@b64-bt-25-461]). The drug requires intravenous infusion since the drug has a short plasma half-life and easily eliminated by the liver. The benefits of tifacogin administration in sepsis, pneumonia, and bacteremia have been investigated without promising results ([@b1-bt-25-461]; [@b33-bt-25-461]; [@b52-bt-25-461]). The synthetic nematode anticoagulant protein (NAPc2), which was originally isolated from the canine hookworm *Ancylostoma canimum*, binds to a non-catalytic site on factor Xa to form a NAPc2-factor-Xa complex and inhibits factor VIIa from binding to TF ([@b97-bt-25-461]). Because of its high affinity binding, NAPc2 has a half-life of about 50 h after subcutaneous administration. Factor VIIa with its active site blocked competes with factor VIIa for TF binding sites, thereby attenuating the initiation of coagulation by the TF-factor VIIa complex ([@b20-bt-25-461])

Factor VIII inhibitors
----------------------

Factor VIII (i.e., anti-hemophilic factor) acts as a cofactor for factor IXa, which activates factor X, thereby, forming an amplification loop ([@b55-bt-25-461]). Partial inhibition of factor VIII appears to be essential to reduce the risk of bleeding because complete inhibition will induce pathological hemophilia. TB-402 is a recombinant human monoclonal antibody that binds with a high affinity to factor VIII, partially inhibiting the action of factor VIII ([@b94-bt-25-461]). It is under phase 2 clinical trials and the exact target of factor VIII inhibition and the degree of inhibition need to be established in further research.

Factor IXa inhibitors
---------------------

The TF-factor VIIa complex activates factor IX, which is relatively stable and diffuses toward activated platelets ([@b43-bt-25-461]). The activated platelets then bind the factor VIIa-IXa complex and recruit factor X for its activation. The activation of factor X by the factor VIIa-IXa complex is nearly 50 times more efficient than the TF-factor VIIa complex ([@b10-bt-25-461]). Therefore, factor IXa represents a prime target for anticoagulation. Defects in factor IXa lead to hemophilia B, while increased concentrations of factor IXa in the blood result in a significantly increased risk of thrombosis formation.

Factor IXa inhibitors including factor IX-directed monoclonal antibodies, factor IXa-directed RNA aptamers (e.g., pegnivacogin), and oral factor IXa inhibitors (e.g., TTP889) have been investigated in humans. SB249417, a chimeric monoclonal antibody directed against the factor IXa, completed a phase I clinical trial, showing a dose-dependent effect on clotting times after continuous infusion ([@b14-bt-25-461]). The REG1 system consisted of pegnivacogin (RB006) and anivamersen (RB007), its complementary control agent being an aptamer-base factor IXa inhibitor that is being investigated for acute coronary syndrome ([@b93-bt-25-461]). Aptamers are small oligonucleotides with high affinity that are used as active drugs. Partial inhibition using TTP889 was not an effective strategy for VTE prophylaxis and TTP889 is currently being investigated for advanced heart failure to determine the potential benefit of attenuated thrombin generation ([@b78-bt-25-461]). Natural factor IX binding proteins and factor IXai are under pre-clinical trials.

Factor XI inhibitors
--------------------

A study showed that factor XI deficiency was associated with a less severe bleeding tendency and a lower incidence of venous thrombosis and stroke, compared to deficiencies of factors VIII or IX, which suggests factor XI is a safe target for anticoagulation. Factor XI inhibition has been extensively studied in both arterial and venous thrombosis in diverse animal models. Antibodies and antisense oligonucleotides (FXI-ASO) against factor XI both showed protective effects in thrombosis without an increased risk of bleeding ([@b11-bt-25-461]). The anti-human factor XI monoclonal antibody was used to prevent vascular graft occlusion in a primate thrombosis model. Similar studies are currently being conducted to ensure the safety of factor XI inhibitors in humans.

Factor XII inhibitors
---------------------

Available data on factor XII was limited but factor XII knockout mice were observed to have protection against pathologic thrombosis while having no hemostasis changes. The selective factor XIIa inhibitor, recombinant human albumin fused to the factor XIIa inhibitor infestin-4 (rHA-infestin-4), was developed ([@b32-bt-25-461]). Inhibition of factor XII is apparently a safe and efficient way of thrombosis prevention, at least in animals. Factor XII antisense, Pro-Phe-Arg-chloromethylketone, Ir-CPI, and several non-specific protein inhibitors are under pre-clinical trials.

Factor Va inhibitors
--------------------

Factor V acts as a cofactor of factor Xa and forms a prothrombinase complex, together with platelet membrane phospholipids. Factor Va inhibitors include drotecogin alpha (activated; DrotAA) and Recomodulin (ART-123), which were initially developed for sepsis-induced thrombosis treatment. DrotAA is a recombinant form of activated protein C with antithrombotic, anti-inflammatory and pro-fibrinolytic properties ([@b19-bt-25-461]). It showed some beneficial effects for coagulation abnormalities associated with severe sepsis but failed to show improvement of patients with severe sepsis. As of 2011, DrotAA was withdrawn from the market.

Recomodulin, a recombinant human thrombomodulin alpha, has shown to be efficacious for VTE prophylaxis following total hip replacement surgery and sepsis-associated disseminated intravascular coagulation (DIC) ([@b46-bt-25-461]; [@b96-bt-25-461]). Thrombomodulin is a thrombin receptor and the thrombin-thrombomodulin complex activates protein C to form activated protein C, which inactivates factors Va and VIIIa ([@b23-bt-25-461]). It has a long plasma half-life after a subcutaneous injection of two to three days, such that it can be given once every five to six days to maintain anticoagulant activity.

Polyphosphate inhibitors
------------------------

Polyphosphate is a polymer of inorganic phosphate residues and is secreted by activated platelets and mast cells. It may initiate and/or accelerate coagulation, acting at several points in the coagulation cascade ([@b79-bt-25-461]). It accelerates the activation of factor V, as well as factor XI by thrombin, and enhances fibrin clot structure increasing its resistance to fibrinolysis ([@b87-bt-25-461]; [@b86-bt-25-461]). A variety of compounds that inhibit polyphosphate and reduce thrombosis are under investigation in animal disease models. Universal heparin reversal agent (UHRA) compounds were studied in mouse models of thrombosis and hemostasis to ensure reduced toxicity and bleeding risk, compared to the toxic substances such as polyethylenimine, polyamidoamine dendrimers, and polymyxin B ([@b92-bt-25-461]).

CONCLUSIONS
===========

The prevention and treatment of VTE is evolving. The new target-specific oral anticoagulants such as oral DTIs and direct factor Xa inhibitors have shifted a paradigm from hospitals to outpatient settings exempting drug monitoring. Current oral anticoagulants available offer predictable, reversible anticoagulant effects with no need for invasive monitoring. However, the major complication of these drugs, bleeding, especially gastrointestinal bleeding, continues to persist, and an optimal management strategy needs to be provided. To date, different categories of anticoagulants are currently under development with unique profiles, along with benefits and potential drawbacks. In the future, the search for safer and more effective oral anticoagulants that have an antidote for rapid reversal will continue.
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Traditional and novel anticoagulants in the market and development

  Generic Name              Mechanism of action                                                                                                       Reversal agents          Anticoagulation monitoring
  ------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------ ----------------------------
  Traditional drugs                                                                                                                                                            
    Warfarin                Deplete coagulation factors II VII, IX, and X through inhibition of cyclic interconversion of vitamin K and its epoxide   Vitamin K                INR
    UFH                     Indirectly inhibit thrombin (factor II), factor X, IX, XI, and XII via enhancing the activity of antithrombin             Protamine sulfate        PT, aPTT
    LMWH                    Inhibit thrombin and factor X via enhancing the activity of antithrombin                                                  Protamine sulfate        Anti-Xa assay
    ULMWH                   Inhibit factor X via enhancing the activity of antithrombin                                                               \-                       Anti-Xa assay
  New drugs                                                                                                                                                                    
    Dabigatran              Inhibit free and fibrin-bound thrombin via direct binding                                                                 Idarucizumab             aPTT, ECT
    Rivaroxaban             Inhibit free and fibrin-bound factor Xa via direct binding                                                                Andexanet alfa, PER977   Anti-Xa assay
    Apixaban                Inhibit free and fibrin-bound factor Xa via direct binding                                                                Andexanet alfa, PER977   Anti-Xa assay
    Edoxaban                Inhibit free and fibrin-bound factor Xa via direct binding                                                                Andexanet alfa, PER977   Anti-Xa assay
  Drugs under development                                                                                                                                                      
    Tifacogin               Inhibit tissue factor-factor VIIa complex                                                                                 \-                       \-
    TB-402                  Inhibit factor VIII via direct binding                                                                                    \-                       \-
    Pegnivacogin            Inhibit factor IX via direct binding                                                                                      \-                       \-
    Factor XI-ASO           Inhibit factor XI via direct binding                                                                                      \-                       \-
    rHA-infestin-4          Inhibit factor XII                                                                                                        \-                       \-
    Recomodulin             Inhibit factor V and VIII via activating protein C through thrombin-thrombomodulin complex                                \-                       \-

aPTT: activated partial thromboplastin time, ASO: antisense oligonucleotide, INR: international Normalized Ratio, ECT: ecarin clotting time, LMWH: low molecular weight heparin, PT: Prothrombin time, UFH: unfractionated heparin, ULMWH: ultra-low molecular weight heparin.
